Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...
Home/KnloSights/Clinical Trial Updates/Clene Provides Regulatory Update on CNM-Au8 for ALS and MS